A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis

Summary

This multicenter, open-label, single arm long-term extension of study WA19926 will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with early, moderate to severe rheumatoid arthritis who have completed the WA19926 core study. Eligible participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.

Timeline

Start

2012-07

Primary completion

2015-02

Completion

2015-02

Outcome

Outcome not reported

Stopped: “Study was terminated by sponsor due to market authorization of tocilizumab for the study population.”

Drugs

Indications